Qilu Pharmaceutical's PD-L1/4-1BB Bispecific Antibody QLF31907 Granted IND Approval by CDE
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
On September 7, the official website of the CDE showed that Qilu Pharmaceutical's PD-L1/4-1BB bispecific antibody QLF31907 was approved for clinical trials.
Source: CDE Official Website
Qilu Pharmaceutical has established a pipeline of over a dozen novel biologic drugs, spanning monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), and antibody-drug conjugates (ADCs). According to the Insight database, Qilu is experiencing a significant surge this year, with seven novel biologics filing their first Investigational New Drug (IND) applications, three of which have already initiated clinical trials. With the exception of the in-licensed product moaozumab, the remainder are all internally developed.
Qilu Pharmaceutical Innovative Biologics Pipeline
Source: Insight Database
*Disclaimer: This article was written by a contributor to Sina Medical News. The views expressed are solely those of the author and do not represent the official position of Sina Medical News.